Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

dispensing solutions, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 160 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committe

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint nation

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 160 mg - diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

physicians total care, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 80 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national comm

Singapūras - anglų - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - hydrochlorothiazide (micronised) - tablet, film coated - 12.5mg

Singapūras - anglų - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - hydrochlorothiazide (micronised) - tablet, film coated - 25mg

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - hydrochlorothiazide 12.5mg;  ; valsartan 160mg;  ;  ;   - film coated tablet - 12.5mg/160mg - active: hydrochlorothiazide 12.5mg   valsartan 160mg       excipient: colloidal silicon dioxide crospovidone ethanol hypromellose iron oxide red macrogol 8000 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. these fixed dose combinations should be used as second line.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - hydrochlorothiazide 12.5mg;  ; valsartan 80mg;  ;  ;   - film coated tablet - 12.5mg/80mg - active: hydrochlorothiazide 12.5mg   valsartan 80mg       excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate powdered cellulose purified talc titanium dioxide - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. these fixed dose combinations should be used as second line.